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Molecular docking analysisa b s t r a c t
Bcl homologs prominently contribute to apoptotic resistance in cancer cells and serve as molecular tar-
gets in treatment of various cancers. Herein, we report the synthesis of biphenyl-adamantane derivatives
by a ligand free palladium on carbon based Suzuki reaction using diisopropylamine as a base for the cou-
pling of adamantane based aryl chloride with a variety of aryl boronic acids. Among the biphenyl deriva-
tives synthesized, compound 30-(adamantan-1-yl)-40-methoxy-[1,10-biphenyl]-3-ol (AMB) displayed
cytotoxic activity against hepatocellular carcinoma cell lines without significantly affecting the normal
cell lines. Further, AMB caused increased accumulation of the HCC cells in subG1 phase, decreased the
expression of Bcl-2, Bcl-xL, cyclin D1, caspase-3, survivin and increased the cleavage of PARP in a
time-dependent manner. In silico molecular interaction studies between Bcl homologs and AMB showed
that the biphenyl scaffold is predicted to form p–p interactions with Phe-101 and Tyr-105 and the ada-
mantyl fragment is predicted to occupy another hydrophobic region in the kink region of the binding
groove. In summary, we report on the synthesis and biological characterization of adamantyl-tethered
biphenylic compounds that induce apoptosis in tumor cells most likely by targeting Bcl homologs.
 2015 Elsevier Ltd. All rights reserved.Aged cells, damaged cells, auto-reactive cells and cells with
irreparable DNA damage are eliminated from the body of all the
multicellular organisms by a complex process of programmed cell
death or apoptosis.1 In multicellular organisms, a balance is main-
tained between the rate of cell division and cell death.2 In case of
oncogenesis, cells exhibit density independent proliferative poten-
tial and resistance to apoptotic signals.3 Bcl-2 family proteins play
a key role in modulation of apoptosis and more than 20 members
of the Bcl-2 family have been discovered and broadly categorized
into pro and antiapoptotic proteins.4,5 BAD, BAK, BAX, PUMA,
NOXA are proapoptotic and Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Bfl-1 are
predominant antiapoptotic proteins of the Bcl-2 protein family.6–8
The equilibrium is maintained between pro and antiapoptotic pro-teins to ensure homeostasis.9,10 Overexpression of antiapoptotic
Bcl-2 family proteins has been demonstrated to contribute to pro-
longed cell survival, resistance to apoptosis, cancer development
and progression, and decreased sensitivity to chemotherapeutics
in cancer cells.11,12 The pro-apoptotic BAD protein interact with
the hydrophobic binding groove of Bcl homologs (Bcl-2 and Bcl-
xL)13 and disrupts the integrity of mitochondria to initiate the
release of cytochrome C into the cytoplasm to induce apopto-
sis.14,15 Therefore, targeting Bcl-2/Bcl-xL proteins using small
molecules that can interact with their hydrophobic socket may
serve as agents with therapeutic potential to induce apoptosis in
cancer cells.
Several heterocycles targeting Bcl homologs have been exten-
sively investigated and few of them have been promoted to clin-
ics.16,17 Navitoclax (ABT-263) is a well-characterized small
molecule inhibitor of Bcl-2 that has been synthesized following a
structure based drug design approach.18 Further structure based
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199 and ABT-737.19,20 In addition, biphenyl based compounds have
been studied extensively and were shown to exhibit very good
antitumor activity against various human malignancies.21,22 Hono-
kiol and magnolol are the biphenyl containing natural compounds
isolated from Magnolia officinalis with an excellent antineoplastic
activity against several cancer types.23,24 The synthetic derivatives
of eugenol have been demonstrated to induce antiproliferative
activity on neuroectodermal tumor cells.25 However, the mecha-
nism of action of these compounds is not clearly understood. In
order to investigate the underlying mechanism of biphenyl deriva-
tives in imparting anticancer activity and in continuation of our
effort to synthesize various organic compounds26–31, we synthe-
sized a series of adamantyl tethered biphenyl derivatives. Ada-
palene is a topical drug in which adamantane substitution at
meta position to the aryl system is seen. Therefore, we considered
meta position as choice of substitution and synthesized biphenyl-
adamantanes and evaluated for their antiproliferative activity
against hepatocellular carcinoma cell lines. We also followed an
in silico approach to explain the role of biphenyls in apoptosis
induction of cancer cells.
The synthetic route for biphenyl-based small molecule libraries
is outlined in Figure 1A. Here we attempted the synthesis of tar-
geted compounds by a ligand free palladium on carbon based
Suzuki reaction using diisopropylamine as a base for the coupling
of adamantane based aryl chloride with a variety of aryl boronic
acids.32–34 Most of the reactions were completed in 4 h with excel-Figure 1. (A) Schematic representation for the synthesis of biphenyl based small molecu
treated with indicated concentrations of AMB, and then subjected to MTT assay after 24,
HCC cell lines in a dose- and time-dependent manner. Navitoclax, a small molecule inh
dependent manner *p < 0.05.lent yields. On the other hand, ortho-substituted boronic acids
showed prolonged reaction time with an exception of ortho methyl
phenyl boronic acid which completed in 4 h. Interestingly, fused
aromatic- and chloro substituted-boronic acids proved to be excel-
lent substrates under the given experimental conditions. The char-
acterization information and the structures of various biphenyl-
adamantanes were provided as Supplementary Table 1.
AMB suppresses the viability of hepatocellular carcinoma (HCC)
cells in a dose- and time-dependent manner: We investigated the
potential effect of novel biphenyl derivatives on HepG2 cells using
a MTT assay as described previously.35–37 We found compounds 3f
(AMB), 3i and 3m to be potent cytotoxic agents against HepG2 cells
and further evaluation revealed that the compounds 3i and 3m sig-
nificantly induce cytotoxicity against normal hepatocytes (LO2)
whereas AMB did not affect the viability of non-transformed cells.
Therefore, 30-(adamantan-1-yl)-40-methoxy-[1,10-biphenyl]-3-ol
(3f, AMB) was found to be most effective cytotoxic agent among
the newly synthesized compounds with the IC50 of 26.1 lM. Fur-
ther, the effect of lead compound on the viability of a panel of three
HCC cell lines (HepG2, Huh7 and Hep3B) at different dose (0, 10,
25, 37.5 and 50 lM) and time points (0, 24, 48 and 72 h) was also
investigated. We found that AMB mitigated the proliferation of
HepG2, Huh7 and Hep3B cell lines in a dose- and time-dependent
manner (Fig. 1B). Navitoclax was used as positive control and
observed the reduction in the percentage of cell viability in dose-
dependent manner (Fig. 1B). All the synthesized compounds were
screened for their cytotoxic activity on LO2 cells. However, exceptles. (B) HCC cells (2.5  104/mL, HepG2, Huh7 and Hep3B) were plated in triplicate,
48 and 72 h to analyze proliferation of cells. AMB suppresses the viability of various
ibitor of Bcl-2/Bcl-xL/Bcl-W also suppressed the viability of HepG2 cells in a dose-
Figure 2. (A) HepG2 cells were treated with different concentrations of AMB and cell cycle distribution was analyzed by staining with propidium iodide. The flow cytometry
analysis revealed that AMB accumulates HepG2 cells in the subG1 phase. (B) Bar diagram showing distribution of HepG2 cells in different phases of cell cycle after treatment
with various concentrations of AMB.
Figure 3. (A) Analysis of Bcl-2 and Bcl-xL expression in AMB treated HepG2 and
MDA-MB-231 cells using western blot analysis. (B) Transfection of HepG2 cells with
Bcl-2 siRNA results in the significant reversal of antiproliferative effect of AMB
compared to cells transfected with control siRNA suggesting that AMB primarily
exerts its cytotoxic effects by negative regulation of Bcl-2 protein *p < 0.05.
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cytotoxicity on LO2 cells thereby indicating that synthesized com-
pounds do not exert cytotoxic effect on normal cells (data not
shown).
AMB causes increased accumulation of HepG2 cells in SubG1 phase:
We next evaluated the effect of AMB on the cell cycle distribution
of HepG2 cells using flow cytometry analysis as described ear-
lier.38,39 Initially, the cells were treated with different concentra-
tions of AMB (0, 10, 20, and 40 lM) for 48 h, fixed with ethanol
and stained with propidium iodide and analyzed for cell cycle dis-
tribution. We observed an increased accumulation of cells in the
subG1 phase in the dose-dependent manner upon AMB treatment
(Fig. 2A and B) and the results further confirm the proapoptotic
effects of AMB.Figure 4. Profiling of expression of apoptotic markers (Caspase-3, PARP), antiapop-
totic protein (Survivin), cell cycle regulator (Cyclin D1) in AMB treated HepG2 cells
using Western blot analysis.
Figure 5. Predicted molecular interactions between Bcl2 and the biphenyl derivatives: Bcl proteins are shown in green cartoon representation with a semi-transparent
surface. (A) A helix from BAD occupies a hydrophobic binding groove in the Bcl2 homolog Bcl-xL (PDB: 2BZW). (B) This binding site can be blocked by synthetic compounds as
shown via the co-crystal structure of Bcl2 and navitoclax (PDB: 4LVT). C, AMB is predicted to occupy the same binding site, thereby using the biphenyl backbone as a-helix
mimetic and positioning the adamantyl moiety in the P4 binding hot-spot.
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Navitoclax interacts with P2 and P4 hotspot of the Bcl-2/Bcl-xL
proteins to serve as a potential inhibitor of Bcl homologs.16 We
further analyzed the expression Bcl-2 and Bcl-xL in AMB treated
HepG2 cells at different time points (0, 12, 18, 24 and 48 h)
using western blotting analysis as described earlier.40,41 Our
results showed that AMB clearly decreased the levels of Bcl-2
and Bcl-xL in the time dependent manner with maximum inhi-
bition observed at 48 h (Fig. 3A). We also investigated the effect
of compound AMB on the expression of anti-apoptotic protein
Bcl-2 and Bcl-xL in breast cancer MDA-MB-231 cells. AMB sub-
stantially downregulated the expression of Bcl-2 in a time-
dependent manner in MDA-MB-231 cells, whereas its potential
effect on the Bcl-xL expression was less substantial as compared
to that on Bcl-2. The levels of b-actin that was used as loading
control remain unchanged upon AMB exposure (Fig. 3A). Next,
we determined whether knockdown of Bcl-2 expression by
siRNA could reverse the antiproliferative effect of AMB in HepG2
cells. Results shown in Figure 3B indicate that the observed
antiproliferative effect of AMB on HepG2 cells was significantly
reversed in cells transfected with Bcl-2 siRNA compared to cells
transfected with control siRNA where there was a dose depen-
dent decrease in cell proliferation (Fig. 3B). These results suggest
that AMB primarily exerts its cytotoxic effects by negative regu-
lation of Bcl-2 protein.
AMB induces apoptosis of HepG2 cells: Activation of caspases,
cleavage of PARP and downregulation of antiapoptotic proteins is
a hallmark event in the cells destined to undergo apoptosis.42–44
During apoptosis, activated caspase-3 cleaves the PARP (116-
kDa) into fragments of 85-kDa and 24-kDA to breakdown the
DNA repair mechanism to drive the cell to apoptosis.45,46 There-
fore, we further evaluated the effect of AMB on the levels of pro-
caspase-3, PARP, survivin and cyclin D1 in HepG2 cells. Figure 4
demonstrates the activation of pro-caspase-3 and concurrent
decrease of full length PARP with an increase in cleaved fragment
(85-kDa) in a time-dependent manner. We further noticed that
treatment of AMB causes the downregulation of survivin (anti-
apoptotic) and cyclin D1 (cell cycle regulator) proteins (Fig. 4)
demonstrating the pro-apoptotic effects of the lead compound.
In silico docking predicted a common binding mode for all com-
pounds of the adamantyl-tethered-biphenylic series: The whole series
of compounds was docked to the co-crystal structure of Bcl-2 with
the anticancer drug navitoclax (PDB: 4LVT)16 using MOE.47 There-fore, we prepared the protein structure using protonate3D from
MOE48 and ionized the ligands for physiological pH using MOE.
Resulting poses were visualized using pymol49 and molecular
interactions were compared to the crystal structure of the pro-
tein–protein interface between Bcl-xL, a close homolog of Bcl2
and BAD (Fig. 5A).13 The biphenyl scaffold of the compounds is
consistently predicted to occupy the hydrophobic binding groove
of Bcl-2 overlapping with the cognate ligand navitoclax (Fig. 5B).
Therefore, complex formation with BAD and thus signaling would
be inhibited. The biphenyl scaffold is predicted to form p–p inter-
actions with Phe-101 and Tyr-105 in Bcl-2. Additionally, Van der
Waals contacts to the aliphatic side-chain of Val-145 are formed.
As the biphenyl scaffold occupied the space of the BAD helix, it
can be considered an a-helix mimetic in agreement with literature
reports.50 The adamantyl fragment is predicted to occupy another
hydrophobic region in the kink region of the binding groove (P4
hot-spot), thereby replacing the phenyl side-chain of Phe-116 of
BAD. Different substitution patterns within the new series are pre-
dicted to interact with the P2 region of Bcl-2. Here, amide-linked
fragments as shown for AMB maintain the position of polar groups
comparable to the cognate ligand navitoclax (Fig. 5C). In conclu-
sion, the overexpression of Bcl-2 family proteins is responsible
for apoptotic resistance in various cancers. Therefore, it opens up
an avenue for the design of small molecules with therapeutic
potential by targeting Bcl-2 family members. Therefore, we synthe-
sized and identified a novel biphenyl-adamantane based Bcl homo-
log inhibitors as biologically active compounds against human
hepatoma cell lines.
Statistical analysis: Student t-test was used to analyze the data.
P < 0.05 was considered statistical significant (*p <0.05; **p <0.005)
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